Bioequivalence of Generic Drugs Commercialised on the Canadian Market

E. Trudel, M. Parent, A. Côté
{"title":"Bioequivalence of Generic Drugs Commercialised on the Canadian Market","authors":"E. Trudel, M. Parent, A. Côté","doi":"10.4172/2329-6631.1000150","DOIUrl":null,"url":null,"abstract":"Several international studies have revealed that there are deficiencies and non bioequivalencies in generic drug reports. The purpose of this study is to determine if monographs were available in both of Canada’s official languages for all generics introduced in the Canadian province of Quebec in 2012 and 2013, if the monographs contained all the required 90% confidence interval for the ratios test/reference of the bioequivalency parameters and if the generics were bioequivalent. From the list of solid oral form of generic drugs marketed in 2012 and 2013 in the Canadian province of Quebec, we downloaded the monographs of generics from Health Canada’s website. We then proceeded to gather information on monograph availability, whether they respected Health Canada’s guidelines and if they were bioequivalent. Our study revealed that in 2012, there were 254 eligible generics, 9.8% of them had no monograph available and only 47.6% were available in both of Canada’s official languages. Similarly for 2013, there were 227 eligible generics, 7.0% of them had no monograph available and only 41.0% were available in both of Canada’s official languages. Overall, only 57.09% of generics in 2012 and 65.20% of generics in 2013 were shown bioequivalent to their reference drug. This data indicates that health care professionals amongst others, lack crucial information to make a responsible decision on the use of generics.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"35 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Developing Drugs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6631.1000150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Several international studies have revealed that there are deficiencies and non bioequivalencies in generic drug reports. The purpose of this study is to determine if monographs were available in both of Canada’s official languages for all generics introduced in the Canadian province of Quebec in 2012 and 2013, if the monographs contained all the required 90% confidence interval for the ratios test/reference of the bioequivalency parameters and if the generics were bioequivalent. From the list of solid oral form of generic drugs marketed in 2012 and 2013 in the Canadian province of Quebec, we downloaded the monographs of generics from Health Canada’s website. We then proceeded to gather information on monograph availability, whether they respected Health Canada’s guidelines and if they were bioequivalent. Our study revealed that in 2012, there were 254 eligible generics, 9.8% of them had no monograph available and only 47.6% were available in both of Canada’s official languages. Similarly for 2013, there were 227 eligible generics, 7.0% of them had no monograph available and only 41.0% were available in both of Canada’s official languages. Overall, only 57.09% of generics in 2012 and 65.20% of generics in 2013 were shown bioequivalent to their reference drug. This data indicates that health care professionals amongst others, lack crucial information to make a responsible decision on the use of generics.
加拿大市场上商业化仿制药的生物等效性
一些国际研究表明,仿制药报告存在缺陷和非生物等效性。本研究的目的是确定2012年和2013年在加拿大魁北克省引入的所有仿制药是否都有加拿大两种官方语言的专论,这些专论是否包含生物等效性参数比率测试/参考所需的所有90%置信区间,以及仿制药是否具有生物等效性。我们从2012年和2013年在加拿大魁北克省上市的固体口服仿制药清单中,下载了加拿大卫生部网站上的仿制药专论。然后我们开始收集关于专著可用性的信息,它们是否遵守加拿大卫生部的指导方针,以及它们是否具有生物等效性。我们的研究显示,2012年有254个符合条件的仿制药,其中9.8%的仿制药没有专著,只有47.6%的仿制药有两种加拿大官方语言。同样,2013年有227个符合条件的仿制药,其中7.0%没有专著,只有41.0%的仿制药有两种加拿大官方语言。总体而言,2012年仅有57.09%的仿制药和2013年仅有65.20%的仿制药显示与其参比药物具有生物等效性。这一数据表明,除其他外,卫生保健专业人员缺乏关键信息,无法对使用非专利药做出负责任的决定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信